‘Anxiety and confusion’ from tariffs and other policies are causing uncertainty says NRF's Kleinhenz
“Economic fundamentals appear solid at this juncture, but uncertainty is pervasive,” Kleinhenz said.
“Economic fundamentals appear solid at this juncture, but uncertainty is pervasive,” Kleinhenz said.
39 Groups support the Biosimilar Red Tape Elimination Act.
He will succeed retiring CEO Michele Buck.
Abby Laursen is the Senior Director of Ads Product Marketing at Snap Inc.
Supporting impacted communities in Central and South Texas.
Starting July 7, 2025 the complete assortment will be available on Ulta.com and will begin rolling out into select Ulta Beauty stores nationwide.
Brigade Capital Management, Macellum Capital Management, and Arkhouse Management Co. partner to purchase Family Dollar
L’Oréal Paris states that Beauty Genius provides a comprehensive beauty service that not only answers questions but also diagnoses, recommends, educates, and simulates beauty results.
The July 6-12 event brings savings on summer and back-to-school items.
A unique opportunity to gain insider perspectives on the business and policy shifts shaping the future of generic medications and patient access to affordable treatments.
The policy would have prevented PBMs from having their compensation linked to the list prices of medications.
Ratner will lead AAM’s government relations team across federal and state relations, advocacy, and alliances.
Welch's Juicefuls Fusions are the first-ever soft and delicious fruit snacks with one flavor on the chewy outside fused with another on the juicy bursting center.
The agreement with Centene will include pharmacist-led initiatives such as medication optimization, which can lead to improved quality of care and outcomes.
LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.
According to GlobalData’s latest report, “Blockbuster Drugs on Patent Cliffs,” there is set to be a smaller proportion of global drug sales which will have patent protection in 2030, a sharp drop compared to previous years.